ecrin-mdr-crcClinical2005Colorectal CancerColorectal NeoplasmsColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2200534Bulgaria8CapecitabineECRIN MDRCompletedfalseA Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon CancerThis study will evaluate the safety and tolerability of capecitabine (Xeloda) in participants who have undergone surgery for colon cancer. Oral Xeloda will be administered twice daily in 3-week cycles for a total of up to 8 cycles. The anticipated time on study treatment is 24 weeks, and the target sample size is 70 individuals.2005-08-152200534NCT02581423